Form 8-K ImmunityBio, Inc. For: Mar 20
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/27/2026
- Wall Street ends mixed as investors focus on tech earnings
- Nvidia in talks with OpenAI to guarantee $250 billion financing for data center, WSJ reports
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Why is Bernstein bullish on memory stocks after Samsung, Nvidia deals?
- Oil prices settle at lowest in over a week, as US pauses attacks on Iran
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Applied Digital (APLD) Tops Q4 EPS by 23c, Revenue Beats
- Wall Street ends mixed as investors focus on tech earnings
ImmunityBio (IBRX) Provides Update on BLA for N-803
March 20, 2023 8:49 AM EDTImmunityBio (NASDAQ: IBRX) continues to explore partnering with a large biopharmaceutical co for commercialization of N-803 for administration intravesically.
continues to engage in ongoing discussions and dialogue with FDA, including proposed label for product candidate under review in... More